Filing Details
- Accession Number:
- 0001649094-24-000126
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-12-19 16:07:14
- Reporting Period:
- 2024-12-18
- Accepted Time:
- 2024-12-19 16:07:14
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1649094 | Vaxcyte Inc. | PCVX | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1230724 | Andrew Guggenhime | C/O Vaxcyte, Inc. 825 Industrial Road, Ste. 300 San Carlos CA 94070 | President And Cfo | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-12-18 | 8,000 | $5.35 | 117,491 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-12-18 | 1,190 | $87.26 | 116,301 | No | 4 | S | Direct | |
Common Stock | Disposition | 2024-12-18 | 3,373 | $88.70 | 112,928 | No | 4 | S | Direct | |
Common Stock | Disposition | 2024-12-18 | 3,157 | $89.31 | 109,771 | No | 4 | S | Direct | |
Common Stock | Disposition | 2024-12-18 | 280 | $90.24 | 109,491 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2024-12-18 | 8,000 | $0.00 | 8,000 | $5.35 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
262,827 | 2030-05-11 | No | 4 | M | Direct |
Footnotes
- The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted May 17, 2024.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $86.84 to $87.82. The reporting person will provide upon request to the SEC, the issuer or security holder of theissuer, full information regarding the number of shares sold at each separate price.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $87.895 to $88.89. The reporting person will provide upon request to the SEC, the issuer or security holder of theissuer, full information regarding the number of shares sold at each separate price.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $88.98 to $89.93. The reporting person will provide upon request to the SEC, the issuer or security holder of theissuer, full information regarding the number of shares sold at each separate price.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $90.095 to $90.41. The reporting person will provide upon request to the SEC, the issuer or security holder of theissuer, full information regarding the number of shares sold at each separate price.
- 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter.